GitLab vs. Oracle: Which Technology Stock Is a Better Buy in 2026?

GitLab posted FY2026 revenue of about $955.2 million, up roughly 25.8% year over year, with positive free cash flow of $222 million but a net loss of about $56 million. Oracle generated nearly $67.4 billion of FY2026 revenue, up about 17.4%, with $17.1 billion in net income and a 25.4% net margin, though free cash flow was negative $23.7 billion due to heavy AI and data center spending. The article favors Oracle over GitLab on scale, profitability, and backlog visibility, while noting litigation and supply-chain risks for Oracle and ongoing losses plus competition for GitLab.

Analysis

Oracle is the cleaner expression of the AI infrastructure trade here, but the market may still be underestimating how capital intensity changes the earnings quality debate. The important second-order effect is that Oracle’s backlog converts today’s spend into visible future cash flows, while GitLab’s growth is still more dependent on usage normalization and enterprise seat expansion, which tends to decelerate faster in a tighter IT budget environment.

The competitive read-through is asymmetric: GitLab’s unified workflow positioning is attractive, but Microsoft and Atlassian can bundle similar functionality into broader platform relationships, making GTLB more vulnerable to pricing pressure than the headline growth rate suggests. By contrast, Oracle’s spending wave should benefit a wider AI hardware and networking ecosystem; the incremental winners likely include NVDA on compute demand and parts of the data-center supply chain, while MSFT faces the risk of customers reallocating budget toward Oracle-hosted infrastructure rather than incremental Microsoft cloud workloads.

The market is probably over-penalizing Oracle’s near-term cash burn because the capex cycle is being treated as a pure expense rather than a capacity pre-sell. The real risk is timing: if supply chain constraints or litigation slow data-center deployment, the backlog won’t convert as quickly and the stock could de-rate over the next 1-3 quarters. For GitLab, the key reversal catalyst would be sustained margin improvement without SBC dilution; absent that, the stock can continue to look optically cheap on P/S but expensive on true equity value creation.

Contrarian take: the consensus may be too focused on profitability optics and not enough on balance-sheet capacity to fund growth. Oracle can actually tolerate a prolonged investment cycle because it has operating leverage and committed demand, while GitLab’s cleaner balance sheet matters less if customer acquisition costs and competitive bundling keep rising. That makes ORCL the higher-conviction long, but GTLB remains interesting only as a volatility-sensitive mean-reversion candidate on drawdowns rather than a core compounder.

Key Decisions for Investors

• Long ORCL on 3-6 month horizon into any post-earnings weakness; use a pullback as entry because backlog visibility should keep multiple compression shallow, with upside from capex-to-revenue conversion and downside protected by installed enterprise demand.
• Pair trade: long ORCL / short GTLB for 2-4 quarters; thesis is that Oracle’s visible AI infrastructure demand should outperform GitLab’s usage-sensitive growth if IT budgets tighten, with better risk/reward from profitability and backlog support.
• Use NVDA as a secondary long against AI infrastructure spend acceleration, but size smaller than ORCL because NVDA already reflects part of the capex cycle; best entry is on any Oracle-guided supply chain scare or AI capex selloff.
• Avoid initiating new long MSFT here if the goal is incremental AI infrastructure beta; Oracle’s current setup offers more direct operating leverage to data-center buildout, while Microsoft’s bundle may face margin drag from defense of platform share.
• For tactical traders, sell downside puts on GTLB only on sharp drawdowns and only if willing to own it as a high-beta software rebound; the risk/reward is acceptable only when the stock dislocates below growth-market multiples and not while SBC remains elevated.